Emerging research suggests that certain diabetes medications could offer benefits beyond blood sugar control, potentially ...

The FDA approved tislelizumab plus chemotherapy for the first-line treatment of unresectable or metastatic gastric or GEJ adenocarcinoma. The FDA has approved tislelizumab-jsgr (Tevimbra) for use with ...

Unfortunately, IBD, as well as treatment, have both steadily increased in the last few years ... This discovery is novel because it is the first time scientists are demonstrating that anti-TNF is the ...

Introduction Acute exacerbation of interstitial lung disease (AE-ILD ... Results Analysis of nine studies (total n=18 509) revealed differential treatment effects based on the ILD subtype. In ...

“As the first and only combination regimen featuring a BRAF-targeted therapy for this patient population, usable even in first-line treatment, the encorafenib regimen has demonstrated high response ...

usable even in first-line treatment, the encorafenib regimen has demonstrated high response rates that are rapid and durable. This represents an encouraging sign of continued disease control and a ...

The compound, named VU319, is the first end-to-end drug discovery effort ... signs of target engagement at the highest dose of the treatment that was tested and saw no side effects typical of ...

Background Evidence regarding high-dose inhaled corticosteroids (HDICS) in asthma exacerbations in adults is insufficient. This study compares the treatment outcomes of HDICS as add-on therapy ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or ...

After excluding any that had macrolides prior to biologics or had missing follow-up data in the first year of biologic ... from electronic patient records. Rates of treatment with oral corticosteroids ...